Paper Details

  1. Home
  2. Paper Details

Calcium influx, oxidative stress, and apoptosis induced by TRPV1 in chronic myeloid leukemia cells: Synergistic effects with imatinib.

Author: AguzziCristina, AmantiniConsuelo, MaggiFederica, MorelliMaria Beatrice, NabissiMassimo, PolidoriCarlo, SantoniGiorgio, ZeppaLaura

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the potential of transient receptor potential vanilloid 1 (TRPV1) activation as a therapeutic strategy for chronic myeloid leukemia (CML). Activation of TRPV1 in CML cells inhibits cell growth and promotes apoptosis by inducing calcium influx, oxidative stress, ER stress, mitochondria dysfunction, and caspase activation.
Paper Details　
Original Abstract of the Article :
<b>Introduction:</b> Calcium flux is the master second messenger that influences the proliferation-apoptosis balance. The ability of calcium flux alterations to reduce cell growth makes ion channels interesting targets for therapy. Among all, we focused on transient receptor potential vanilloid 1, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975599/

データ提供：米国国立医学図書館（NLM）

Calcium influx, oxidative stress, and apoptosis induced by TRPV1 in chronic myeloid leukemia cells: Synergistic effects with imatinib

This research delves into the intricate world of chronic myeloid leukemia (CML), a type of cancer that affects the blood and bone marrow. Imagine a camel caravan struggling to survive in a desert where a deadly disease threatens their health. This research explores the potential of targeting a specific ion channel, transient receptor potential vanilloid 1 (TRPV1), to combat CML cells.

A new avenue for treating chronic myeloid leukemia

This research suggests that activating TRPV1 can effectively inhibit the growth of CML cells and promote their apoptosis. Just as a skilled caravan leader finds ways to overcome obstacles and keep their camels healthy, researchers are seeking new ways to target and eliminate CML cells. The study highlights the potential of TRPV1 activation, especially when combined with the standard drug imatinib, to improve treatment outcomes.

Hope for a healthier future

This study offers a glimmer of hope for individuals battling CML. Imagine a camel caravan overcoming challenges and reaching a safe destination. This research suggests that activating TRPV1 could be a promising strategy to enhance existing therapies and improve the management of this debilitating disease.

Dr.Camel's Conclusion

This research explores the exciting potential of targeting TRPV1 in the treatment of CML. Just as a caravan navigates a desert, searching for ways to overcome obstacles and find a path to safety, researchers are diligently seeking innovative solutions for a healthier future for those living with CML.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-07
Further Info :

Pubmed ID

36876044

DOI: Digital Object Identifier

PMC9975599

Related Literature

Article Analysis
・Effects of imatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.